Work

ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer's disease

Year: 2009

Type: article

Source: The Pharmacogenomics Journal

DOI: 10.1038/tpj.2009.58

Authors: D J Stone, C Molony, C Suver, E E Schadt, W Z Potter

Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Sage Bionetworks, Pacific Biosciences (United States)

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1969050262

FWCI: 0.882

Cites: 16

Cited by: 19

Related to: 10